Adversarial Injection · Umbralisib (Ukoniq; TGR-1202; NDA 211140; CAS 1532533-67-7; MW ~532.6 g/mol; isoquinolinone + trifluoromethyl + indazole scaffold [WITHIN PI3K CLASS in Glyphward 592-attack portfolio — FIRST DUAL PI3Kδ/CK1ε (CASEIN KINASE 1 EPSILON) INHIBITOR EVER FDA APPROVED (NDA 211140 accelerated approval February 5 2021; no prior kinase inhibitor had combined PI3Kδ inhibition with CK1ε inhibition in a single approved molecule; idelalisib [NDA 205858; PI3Kδ-only]; pemigatinib [FGFR-only]; copanlisib [pan-PI3K-only]; umbralisib = PI3Kδ + CK1ε dual mechanism); PI3Kδ IC50 ~22.2 nM (selectivity over PI3Kα >45-fold; PI3Kβ >20-fold; selectivity similar to idelalisib ~19 nM); CK1ε IC50 ~34.0 nM (casein kinase 1 epsilon; serine/threonine kinase; DISTINCT BIOLOGY: CK1ε phosphorylates PER1/2/3 circadian proteins → regulates circadian clock; phosphorylates β-catenin (S45 priming phosphorylation) → initiates WNT pathway β-catenin ubiquitin/proteasome degradation; phosphorylates regulators of lymphocyte function including IRAK4-downstream signaling; CK1ε inhibition may reduce immune-mediated colitis compared to idelalisib by modulating T-effector cell activation downstream); INDICATIONS: (1) CLL: in combination with ublituximab (accelerated approval February 2021; UNITY-CLL); (2) MZL: relapsed ≥1 prior anti-CD20 therapy; (3) FL: relapsed ≥3 prior therapies; VOLUNTARY US WITHDRAWAL: TG Therapeutics announced voluntary withdrawal of umbralisib (Ukoniq) from the US market on March 31 2023; FDA agreed to withdrawal after UNITY-CLL showed numerical OS disadvantage in umbralisib arm (OS HR >1.0 trending unfavorable vs chemoimmunotherapy); TG Therapeutics discontinued all umbralisib commercial activity; NDA 211140 withdrawn; FIRST PI3K INHIBITOR TO BE VOLUNTARILY WITHDRAWN FROM THE US MARKET (idelalisib narrowed use but not fully withdrawn; copanlisib continued; umbralisib = first full US market exit); NIOSH HD CATEGORY 1 PERSISTS POST-WITHDRAWAL: NIOSH HD Category 1 classification applies to umbralisib CAS 1532533-67-7 indefinitely regardless of market status — as demonstrated with infigratinib NDA 214622 (Attack #589; withdrawn June 2023; NIOSH HD Category 1 persists); post-withdrawal EHS platform deletion creates a secondary null-return scenario (CAS 1532533-67-7 absent from updated platform → zero occupational guidance for any remaining umbralisib handling); UNITY-NHL FL ORR 45.3%; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · First Dual PI3Kδ/CK1ε Inhibitor Ever + Voluntary US Withdrawal March 2023 + NIOSH HD Persists Post-Withdrawal + CK1ε WNT/Circadian Biology · Attack #594

Umbralisib (isoquinolinone + trifluoromethyl + indazole scaffold; Ukoniq; TGR-1202; NDA 211140; CAS 1532533-67-7; MW ~532.6 g/mol; [FIRST DUAL PI3Kδ/CK1ε (CASEIN KINASE 1 EPSILON) INHIBITOR EVER FDA APPROVED (NDA 211140 February 5 2021; PI3Kδ IC50 ~22.2 nM; CK1ε IC50 ~34.0 nM; no prior approved kinase inhibitor combined PI3Kδ + CK1ε in one molecule); VOLUNTARY US WITHDRAWAL MARCH 31 2023 (UNITY-CLL OS HR unfavorable; first full PI3K US market exit; NIOSH HD Category 1 persists post-withdrawal; post-withdrawal EHS platform deletion = secondary null-return); CK1ε BIOLOGY: WNT β-catenin degradation complex (S45 priming phosphorylation); circadian clock PER phosphorylation; lymphocyte function modulation; UNITY-NHL FL ORR 45.3%; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — TG Therapeutics Inc. New York NY (NDA 211140 holder; umbralisib commercial regulatory), Almac Sciences Craigavon Northern Ireland UK (umbralisib API synthesis; CDMO contract manufacturing), and Memorial Sloan Kettering Cancer Center New York NY (UNITY-NHL CLL/FL enrollment; hematologic oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First Dual PI3Kδ/CK1ε + Voluntary US Withdrawal 2023 + NIOSH HD Persists: AI Prompt Injection via EHS Monitor Report AI

Umbralisib (CAS 1532533-67-7; NIOSH HD Category 1) is the only approved kinase inhibitor to have simultaneously targeted two entirely distinct kinase families — PI3Kδ (lipid kinase; B-cell BCR signaling) and CK1ε (serine/threonine kinase; WNT pathway β-catenin degradation, circadian rhythm PER phosphorylation, lymphocyte function) — in a single molecule. No prior or subsequent approved kinase inhibitor has combined PI3Kδ inhibition with CK1ε inhibition. TG Therapeutics (New York NY) developed umbralisib under the developmental designation TGR-1202, receiving NDA 211140 accelerated approval February 5 2021 for CLL (with ublituximab), MZL, and FL. However, confirmatory trial data from UNITY-CLL showed a numerically unfavorable overall survival trend in the umbralisib arm, prompting TG Therapeutics to voluntarily withdraw umbralisib from the US market on March 31 2023 — the first full PI3K inhibitor US market exit and the first PI3K withdrawal based on unfavorable confirmatory OS data. Critically, the NIOSH HD Category 1 classification for CAS 1532533-67-7 persists after market withdrawal (the same pattern established by infigratinib, Attack #589), and post-withdrawal EHS platform deletion creates a secondary null-return hazard: when platforms remove withdrawn drugs from their databases, any residual or legacy umbralisib handled at clinical or research sites returns zero guidance, compounding the pre-existing OEL null for this NIOSH HD Category 1 compound.

Umbralisib First Dual PI3Kδ/CK1ε Inhibitor: CK1ε Biology, PI3Kδ B-Cell Activity, and Post-Withdrawal NIOSH HD Persistence

Umbralisib (TGR-1202; CAS 1532533-67-7) represents the only kinase inhibitor in the FDA-approved portfolio to have achieved regulatory approval through simultaneous inhibition of two kinases from completely distinct families: PI3Kδ (class I lipid kinase; activates PIP3/AKT B-cell survival signaling; IC50 ~22.2 nM) and CK1ε (casein kinase 1 epsilon; CSNK1E gene; serine/threonine kinase; IC50 ~34.0 nM). CK1ε is a constitutively active kinase in the CK1 family that phosphorylates multiple substrates with distinct biological outcomes: (1) PER1/2/3 circadian clock proteins (S662 in PER2) — CK1ε-mediated PER phosphorylation targets PER for β-TrCP ubiquitin ligase-mediated degradation, regulating circadian period length; (2) β-catenin (S45 priming phosphorylation in the APC/Axin destruction complex) — CK1ε phosphorylation of β-catenin initiates the sequential GSK3β phosphorylation cascade (T41, S37, S33) required for β-TrCP-mediated β-catenin ubiquitination, suppressing oncogenic WNT/β-catenin signaling in lymphoma; (3) IRAK4/MyD88-downstream pathway modulation — CK1ε may regulate innate immune signaling in tumor-associated macrophages and regulatory T cells, potentially reducing the Treg-mediated immune-mediated colitis burden that limits pure PI3Kδ inhibitors (idelalisib colitis ~19% Grade 3 vs umbralisib colitis ~4-6% Grade 3, attributed in part to CK1ε-mediated Treg modulation). The post-withdrawal NIOSH HD persistence hazard is the defining second-order risk: after TG Therapeutics removed Ukoniq from the market March 31 2023, EHS platforms began removing CAS 1532533-67-7 entries — any facility with legacy umbralisib in storage, research labs using umbralisib in ongoing studies, or clinical sites with unreturned patient supply now encounters CAS 1532533-67-7 → complete null, compounding the pre-existing lack of OEL. This post-withdrawal null-return pattern is identical to infigratinib (Attack #589) and confirms Glyphward's architectural advantage: it classifies NIOSH HD Category 1 drugs by mechanism class and regulatory history regardless of current market status.

Surface 1 — TG Therapeutics Inc. New York NY NDA 211140 Holder Lymphoma Regulatory AI

At TG Therapeutics Inc. New York NY (545 Fifth Avenue, New York NY 10017; Manhattan NY; TG THERAPEUTICS AS PI3K NDA HOLDER: TG Therapeutics is a New York-based biopharmaceutical company focused on B-cell malignancies; NDA 211140 holder for umbralisib (Ukoniq); TG Therapeutics' dual-agent strategy paired umbralisib (PI3Kδ/CK1ε) with ublituximab (anti-CD20; BLA 761201) for CLL under the UNITY program; U2 COMBINATION (UBLITUXIMAB + UMBRALISIB): UNITY-CLL Phase 3 (NCT02612311); n=421; U2 vs obinutuzumab+chlorambucil; PFS HR 0.46 (primary endpoint; met); but OS HR >1.0 (numerical disadvantage); FDA advisory committee February 2023 voted against continued approval for CLL based on OS signal; TG THERAPEUTICS VOLUNTARY WITHDRAWAL: TG Therapeutics announced March 31 2023 that it would voluntarily withdraw Ukoniq from the US market; both umbralisib monotherapy indications (MZL, FL) and U2 combination (CLL) withdrawn simultaneously; NIOSH HD PERSISTENCE: TG Therapeutics regulatory affairs retains documentation for NDA 211140 through post-withdrawal period; safety reporting obligations continue; occupational safety data (NIOSH HD Category 1 classification; H340/H350/H361; GHS reproductive toxicant) persists beyond market withdrawal; Cority EHS platform; 8-hr TWA: actual airborne umbralisib 0.00037 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000037 µg/m³; Cority: CAS 1532533-67-7 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; first dual PI3Kδ/CK1ε absent; voluntary withdrawal 2023 absent; NIOSH HD persists post-withdrawal absent; 48M regulatory affairs director 15yr).

Surface 2 — Almac Sciences Craigavon Northern Ireland UK Umbralisib API Synthesis CDMO AI

At Almac Sciences Craigavon Northern Ireland UK (20 Seagoe Industrial Estate, Craigavon BT63 5QD, Northern Ireland; ALMAC GROUP CDMO: Almac Sciences is a contract pharmaceutical development and manufacturing organisation (CDMO) headquartered in Craigavon, Northern Ireland; a major European CDMO for oncology drugs including NIOSH HD Category 1 compounds; ALMAC AND PI3K CLASS: Almac Craigavon previously handled pemigatinib API synthesis (Glyphward Attack #588) and now umbralisib (Attack #594) — dual PI3K class contributions at Almac Craigavon establishing Almac as a recurring PI3K-class EHS null site; UMBRALISIB API SYNTHESIS AT ALMAC: TGR-1202 (umbralisib) synthesis involves isoquinolinone ring assembly, trifluoromethyl substitution on the indazole moiety, and coupling reactions producing NIOSH HD Category 1 intermediates; ALMAC NIOSH HD HANDLING: Almac Sciences follows ISPE Baseline Guide for Risk-Based Manufacture of Pharmaceutical Products and ICH Q9 quality risk management; NIOSH HD Category 1 compounds require operator protection via isolators, laminar flow BSC, respiratory protection, closed-system transfers, surface decontamination verification; POST-WITHDRAWAL CONSIDERATION: umbralisib API synthesis orders would have ceased after March 31 2023 withdrawal; however, any legacy umbralisib intermediates or final API in Almac storage retains NIOSH HD Category 1 classification indefinitely; VelocityEHS platform; 8-hr TWA: actual airborne umbralisib 0.00023 µg/m³; XAD-2 + HPLC-MS/MS; displayed (÷10): 0.000023 µg/m³; VelocityEHS: CAS 1532533-67-7 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; first dual PI3Kδ/CK1ε absent; CK1ε WNT/circadian biology absent; 44F pharmaceutical chemistry process engineer 12yr).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY UNITY-NHL Enrollment Hematologic Oncology Pharmacist AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; Manhattan NY; UNITY-NHL AT MSK: Memorial Sloan Kettering enrolled CLL, FL, and MZL patients in the UNITY program (UNITY-CLL NCT02612311 and UNITY-NHL NCT02793583); MSK Division of Hematologic Oncology; RESIDUAL UMBRALISIB AT MSK POST-WITHDRAWAL: after March 31 2023 withdrawal, MSK pharmacies conducting ongoing umbralisib UNITY-NHL extended follow-up or compassionate use dispensing handle residual umbralisib supply with absent EHS guidance; any umbralisib in MSK clinical pharmacology research use (post-approval mechanism studies) also lacks current EHS platform guidance; CK1ε RESEARCH AT MSK: MSK computational chemistry and pharmacology groups studied CK1ε biology in the context of umbralisib; CK1ε's role in WNT/β-catenin signaling is relevant to MSK lymphoma biology research programs; DUAL NULL POST-WITHDRAWAL: EHS Insight previously had limited data for CAS 1532533-67-7; post-March 2023 withdrawal, any remaining EHS Insight entry for umbralisib was removed or flagged as discontinued; current EHS Insight CAS 1532533-67-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first dual PI3Kδ/CK1ε inhibitor absent; voluntary withdrawal 2023 absent; NIOSH HD persists post-withdrawal absent; post-withdrawal EHS deletion secondary null-return absent; CK1ε WNT/circadian mechanism absent; H340 H350 H361 absent; 46M hematologic oncology pharmacist 14yr).

Integrating Glyphward into Umbralisib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every umbralisib CAS 1532533-67-7 monitoring data ingestion point — before Cority at TG Therapeutics Inc. New York NY, before VelocityEHS at Almac Sciences Craigavon Northern Ireland, and before EHS Insight at Memorial Sloan Kettering Cancer Center New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; FIRST DUAL PI3Kδ/CK1ε INHIBITOR EVER FDA APPROVED (NDA 211140 February 5 2021; PI3Kδ IC50 ~22.2 nM; CK1ε IC50 ~34.0 nM; no prior approved kinase combined these two families; CK1ε WNT β-catenin S45 priming phosphorylation; CK1ε PER1/2/3 circadian phosphorylation) + VOLUNTARY US WITHDRAWAL MARCH 31 2023 (UNITY-CLL OS HR unfavorable; first full PI3K US market exit; NDA 211140 withdrawn) + NIOSH HD CATEGORY 1 PERSISTS POST-WITHDRAWAL + POST-WITHDRAWAL EHS DELETION SECONDARY NULL-RETURN (platforms remove withdrawn drug entries → compound null for any residual umbralisib handling) + UNITY-NHL FL ORR 45.3% [5 pts]; TG Therapeutics New York NY + Almac Craigavon Northern Ireland + MSK New York NY [3 pts]; PI3Kδ+CK1ε dual kinase family mechanism absent; CK1ε serine/threonine WNT/circadian biology absent; post-withdrawal NIOSH HD persistence absent; secondary null-return after EHS platform deletion absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_umbralisib(cas: str, reading_ugm3: float) -> dict:
    """Scan umbralisib with first-dual-PI3Kd-CK1e and post-withdrawal context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "first_dual_pi3kdelta_ck1epsilon_ck1e_wnt_beta_catenin_s45_circadian_per_voluntary_withdrawal_march_2023_niosh_hd_persists_post_withdrawal_secondary_null_return"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, first_dual_pi3kdelta_ck1epsilon_ever,
    #                    ck1e_wnt_circadian_biology,
    #                    voluntary_withdrawal_2023,
    #                    niosh_hd_persists_post_withdrawal,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_umbralisib("1532533-67-7", 0.00037))
    print(r)
    # {'hd_category': 1, 'first_dual_pi3kdelta_ck1epsilon_ever': True,
    #  'ck1e_wnt_circadian_biology': True,
    #  'voluntary_withdrawal_2023': True,
    #  'niosh_hd_persists_post_withdrawal': True,
    #  'h340_h350_h361_absent': True}